EP2091969A4 - Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes - Google Patents

Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes

Info

Publication number
EP2091969A4
EP2091969A4 EP07812601A EP07812601A EP2091969A4 EP 2091969 A4 EP2091969 A4 EP 2091969A4 EP 07812601 A EP07812601 A EP 07812601A EP 07812601 A EP07812601 A EP 07812601A EP 2091969 A4 EP2091969 A4 EP 2091969A4
Authority
EP
European Patent Office
Prior art keywords
polypeptides
related methods
cytotoxic properties
reduced increased
antiinflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07812601A
Other languages
German (de)
English (en)
Other versions
EP2091969A2 (fr
Inventor
Falk Nimmerjahn
Yoshikatsu Kaneko
Jeffrey V Ravetch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/041791 external-priority patent/WO2007055916A2/fr
Priority claimed from PCT/US2007/008396 external-priority patent/WO2007117505A2/fr
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of EP2091969A2 publication Critical patent/EP2091969A2/fr
Publication of EP2091969A4 publication Critical patent/EP2091969A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP07812601A 2006-10-27 2007-07-03 Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes Ceased EP2091969A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2006/041791 WO2007055916A2 (fr) 2005-11-07 2006-10-27 Reactifs, procedes et systemes pour la selection d'un anticorps cytotoxique ou d'une variante
PCT/US2007/008396 WO2007117505A2 (fr) 2006-04-05 2007-04-03 Polypeptides presentant des proprietes anti-inflammatoires accrues et des proprietes cytotoxiques reduites, et procedes coorespondants
PCT/US2007/072771 WO2008057634A2 (fr) 2006-10-26 2007-07-03 Polypeptides ayant des propriétés antiinflammatoires accrues et cytotoxiques réduites et procédés associés

Publications (2)

Publication Number Publication Date
EP2091969A2 EP2091969A2 (fr) 2009-08-26
EP2091969A4 true EP2091969A4 (fr) 2010-05-12

Family

ID=39367532

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07812601A Ceased EP2091969A4 (fr) 2006-10-27 2007-07-03 Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes

Country Status (3)

Country Link
EP (1) EP2091969A4 (fr)
AU (1) AU2007317755A1 (fr)
WO (1) WO2008057634A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2647524C (fr) 2006-04-05 2019-11-26 The Rockefeller University Polypeptides presentant des proprietes anti-inflammatoires accrues et des proprietes cytotoxiques reduites, et procedes coorespondants
BRPI0910091A2 (pt) 2008-03-27 2017-05-30 Novozymes As processo para produzir um produto de fermentação
WO2009132130A2 (fr) 2008-04-22 2009-10-29 The Rockefeller University Procédés d'identification de composés anti-inflammatoires
EP2233499A1 (fr) 2009-03-26 2010-09-29 CSL Behring AG Composition d'anticorps avec Fab sialylation altérée
EP2233502A1 (fr) * 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Anticorps spécifiques à l'antigène syalilé pour le traitement ou prophylaxie des réactions immunitaires inflammatoires non désirables et leurs procédés de production
EP2427497B1 (fr) 2009-05-07 2016-12-07 Stallergenes Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
SG177764A1 (en) 2009-07-30 2012-03-29 Hoffmann La Roche Enzymatic antibody processing
WO2011138354A1 (fr) 2010-05-07 2011-11-10 Csl Behring Ag Composition d'anticorps obtenus par fractionnement d'immunoglobulines plasmatiques par chromatographie d'affinité sur une colonne d'affinité de sambucus nigra
WO2012012590A2 (fr) 2010-07-23 2012-01-26 Novozymes A/S Procédés pour produire des produits de fermentation
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof
WO2012068134A1 (fr) * 2010-11-15 2012-05-24 Biogen Idec Inc. Enrichissement et concentration d'isoformes de produit choisis par liaison surchargée et chromatographie d'élution
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2710032B1 (fr) 2011-05-20 2019-12-25 Momenta Pharmaceuticals, Inc. Glycoprotéines modifiées
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
SG2014012470A (en) 2011-10-05 2014-06-27 Hoffmann La Roche Process for antibody g1 glycoform production
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9663581B2 (en) 2012-04-25 2017-05-30 Momenta Pharmaceuticals, Inc. Modified glycoproteins
EP2877589B1 (fr) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoprotéines ayant des propriétés anti-inflammatoires
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2900264A4 (fr) * 2012-09-26 2016-05-25 Momenta Pharmaceuticals Inc Préparations de glycoprotéines
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
WO2014186310A1 (fr) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Méthodes de traitement de la neurodégénérescence
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (fr) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN117924477A (zh) 2017-12-19 2024-04-26 洛克菲勒大学 具有改进的效应子功能的人IgG Fc结构域变体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039488A1 (fr) * 1995-06-06 1996-12-12 Genentech, Inc. Procede de regulation de la sialylation de proteines produites par une culture de cellules de mammiferes
WO2000063403A2 (fr) * 1999-04-15 2000-10-26 Crucell Holland B.V. Production de proteine de recombinaison dans une cellule humaine
WO2004058944A2 (fr) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Amelioration de la qualite d'un produit dans des procedes de culture de cellules mammiferes en vue de produire des proteines
WO2005063808A1 (fr) * 2003-12-31 2005-07-14 Merck Patent Gmbh Proteine hybride fc-erythropoietine a pharmacocinetique amelioree
WO2007005786A2 (fr) * 2005-06-30 2007-01-11 Centocor, Inc. Procedes et compositions a effet therapeutique ameliore

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039488A1 (fr) * 1995-06-06 1996-12-12 Genentech, Inc. Procede de regulation de la sialylation de proteines produites par une culture de cellules de mammiferes
WO2000063403A2 (fr) * 1999-04-15 2000-10-26 Crucell Holland B.V. Production de proteine de recombinaison dans une cellule humaine
WO2004058944A2 (fr) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Amelioration de la qualite d'un produit dans des procedes de culture de cellules mammiferes en vue de produire des proteines
WO2005063808A1 (fr) * 2003-12-31 2005-07-14 Merck Patent Gmbh Proteine hybride fc-erythropoietine a pharmacocinetique amelioree
WO2007005786A2 (fr) * 2005-06-30 2007-01-11 Centocor, Inc. Procedes et compositions a effet therapeutique ameliore

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DALZIEL MARTIN ET AL: "Lectin analysis of human immunoglobulin G N-glycan sialylation", GLYCOCONJUGATE JOURNAL, vol. 16, no. 12, December 1999 (1999-12-01), pages 801 - 807, XP002575135, ISSN: 0282-0080 *
JASSAL R ET AL: "Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 17 AUG 2001, vol. 286, no. 2, 17 August 2001 (2001-08-17), pages 243 - 249, XP002574380, ISSN: 0006-291X *
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075 *
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1129594 *
NIMMERJAHN FALK ET AL: "The antiinflammatory activity of IgG: the intravenous IgG paradox", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 204, no. 1, January 2007 (2007-01-01), pages 11 - 15, XP002575137, ISSN: 0022-1007 *
RAJU T SHANTHA ET AL: "Glycoengineering of therapeutic glycoproteins: In vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 40, no. 30, 31 July 2001 (2001-07-31), pages 8868 - 8876, XP002461128, ISSN: 0006-2960 *
SCALLON ET AL: "Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 7, November 2006 (2006-11-01), pages 1524 - 1534, XP005792683, ISSN: 0161-5890 *
See also references of WO2008057634A2 *
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED .ALPHA.-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 263, no. 10, 5 April 1988 (1988-04-05), pages 4576 - 4585, XP002575136, ISSN: 0021-9258 *
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED ALPHA-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 10, 1988, pages 4576 - 4585, XP002575136, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP2091969A2 (fr) 2009-08-26
WO2008057634A2 (fr) 2008-05-15
AU2007317755A1 (en) 2008-05-15
WO2008057634A3 (fr) 2008-12-04

Similar Documents

Publication Publication Date Title
EP2091969A4 (fr) Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes
BRPI0719369A2 (pt) Porta-prótese e aplicações do mesmo
GB2446843B (en) Amplifier circuit and methods of operation thereof
EP1967207A4 (fr) Inhibiteur de l'induction des cellules t cytotoxiques
EP2010566A4 (fr) Polypeptides présentant des propriétés anti-inflammatoires accrues et des propriétés cytotoxiques réduites, et procédés correspondants
IL196799A0 (en) Fused heterocyclic derivative and use thereof
DK3207941T6 (da) Fremgangsmåder og sammensætninger baseret på diphtheritoksin-interleukin-3-konjugater
EP1987184A4 (fr) Pièces carbone/carbone et procédés pour les fabriquer
EP2007877A4 (fr) Procedes d'agregation compacte de cellules dermiques
EP2038947A4 (fr) Récipient de liquide et procédés associés
DE602007010272D1 (de) Parkhilfevorrichtung und parkhilfeverfahren
EP2197380A4 (fr) Instrument et procédé électro-chirurgical
GB0904193D0 (en) Powered wheelchair having an articulating beam and related methods of use
DK2069312T3 (da) Pyridazinonderivater
IL192581A0 (en) Rage fusion proteins and methods of use
TWI349426B (en) Bias circuit and power amplifier
EP1972256A4 (fr) Endoscope et endoscope rotatif auto-moteur
EP1991565A4 (fr) Protéines chimériques du toxoïde de shiga
IL197543A0 (en) Molecular switches and methods for their use
DE602007006573D1 (de) Magnetische Teilchen und Herstellungsverfahren dafür
DK1989220T3 (da) HIV-fusionsinhibitorpeptider med forbedrede biologiske egenskaber
EP2066174A4 (fr) Compositions contenant de l'alpha-1-antitrypsine et leurs procédés d'utilisation
DK2099304T3 (da) Carboranylporfyriner og anvendelser deraf
DK2023668T3 (da) Høreapparat med visualiserede psykoakustiske variable og tilsvarende fremgangsmåde
DK1937332T3 (da) Infusionsapparat og aktuator hertil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090519

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAVETCH, JEFFREY V.

Inventor name: NIMMERJAHN, FALK

Inventor name: KANEKO, YOSHIKATSU

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE ROCKEFELLER UNIVERSITY

A4 Supplementary search report drawn up and despatched

Effective date: 20100414

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135408

Country of ref document: HK

17Q First examination report despatched

Effective date: 20100719

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135408

Country of ref document: HK